These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28952470)

  • 1. [The efficacy and safety of pitavastatin].
    Sansoy V
    Turk Kardiyol Dern Ars; 2017 Apr; 45(Suppl 3):1-4. PubMed ID: 28952470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pitavastatin: A Review in Hypercholesterolemia.
    Hoy SM
    Am J Cardiovasc Drugs; 2017 Apr; 17(2):157-168. PubMed ID: 28130659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia.
    Ose L; Budinski D; Hounslow N; Arneson V
    Atherosclerosis; 2010 May; 210(1):202-8. PubMed ID: 20080236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
    da Silva PM
    Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pitavastatin: clinical effects from the LIVES Study.
    Teramoto T
    Atheroscler Suppl; 2011 Nov; 12(3):285-8. PubMed ID: 22152283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pitavastatin - results from phase III & IV.
    Betteridge J
    Atheroscler Suppl; 2010 Dec; 11(3):8-14. PubMed ID: 21193153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.
    Sansanayudh N; Wongwiwatthananukit S; Putwai P; Dhumma-Upakorn R
    Ann Pharmacother; 2010 Mar; 44(3):415-23. PubMed ID: 20179259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study.
    Kurogi K; Sugiyama S; Sakamoto K; Tayama S; Nakamura S; Biwa T; Matsui K; Ogawa H;
    J Cardiol; 2013 Aug; 62(2):87-94. PubMed ID: 23672789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C.
    Teramoto T
    Expert Opin Pharmacother; 2012 Apr; 13(6):859-65. PubMed ID: 22332608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pitavastatin - from clinical trials to clinical practice.
    Masana L
    Atheroscler Suppl; 2010 Dec; 11(3):15-22. PubMed ID: 21193154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pitavastatin: an overview.
    Saito Y
    Atheroscler Suppl; 2011 Nov; 12(3):271-6. PubMed ID: 22152281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
    Gumprecht J; Gosho M; Budinski D; Hounslow N
    Diabetes Obes Metab; 2011 Nov; 13(11):1047-55. PubMed ID: 21812889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pitavastatin demonstrates long-term efficacy, safety and tolerability in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia.
    Stender S; Budinski D; Hounslow N
    Eur J Prev Cardiol; 2013 Feb; 20(1):29-39. PubMed ID: 22345687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia.
    Duggan ST
    Drugs; 2012 Mar; 72(4):565-84. PubMed ID: 22356292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Searching the place of pitavastatin in the current treatment of patients with dyslipidemia.
    Barrios V; Escobar C; Zamorano JL
    Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1597-612. PubMed ID: 24215190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia.
    Park S; Kang HJ; Rim SJ; Ha JW; Oh BH; Chung N; Cho SY
    Clin Ther; 2005 Jul; 27(7):1074-82. PubMed ID: 16154486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial.
    Eriksson M; Budinski D; Hounslow N
    Adv Ther; 2011 Sep; 28(9):811-23. PubMed ID: 21874538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.